Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating the Effects of Transcranial Magnetic Stimulation With Intracranial EEG in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03702127
Recruitment Status : Active, not recruiting
First Posted : October 10, 2018
Last Update Posted : October 10, 2018
Sponsor:
Information provided by (Responsible Party):
Aaron Boes, University of Iowa

Brief Summary:
This is a study looking at the effects of transcranial magnetic stimulation (TMS) on the human brain as recorded by intracranial electroencephalography in neurosurgical patients. TMS will be applied in single or repetitive pulses and responses will be recorded.

Condition or disease Intervention/treatment Phase
Epilepsy Intractable Device: Transcranial magnetic stimulation Not Applicable

Detailed Description:
Transcranial magnetic stimulation (TMS) is a noninvasive method of focally stimulating the brain that uses electromagnetic induction and does not require surgery. There is optimism that TMS will revolutionize how we treat neurological and psychiatric disorders, evidenced by over 1000 clinical trials registered using TMS. Much of this optimism stems from the successful use of TMS as a treatment for depression. Despite the large number of clinical trials using TMS the number of therapeutic indications has been stagnant, limited to major depression and more recently obsessive-compulsive disorder. There are fundamental questions about the underlying mechanisms of action for TMS that will be critical to understand in order to advance this treatment modality. Here, we propose a unique collaborative project between neurology and neurosurgery that will allow an unprecedented window into understanding how TMS impacts the human brain. Specifically, we will perform TMS in neurosurgical patients with intracranial electroencephalography (iEEG) monitoring to record real time effects of TMS on local and remote brain areas with an unparalleled combination of spatial and temporal resolution relative to other human studies. We have already demonstrated the safety of this approach using a gel-based phantom brain and have results from seven patients demonstrating safety and preliminary results. For the current proposal we aim to: 1) characterize the response of TMS on the human brain as recorded from iEEG between active and sham conditions, and 2) relate remote electrophysiological responses from TMS to measures of brain connectivity between the stimulation & recording sites assessed with resting state functional connectivity MRI (rs-fcMRI). This will allow us to evaluate the relationship between TMS-evoked iEEG responses and the strength of functional connectivity to the stimulation site in a regression model. We hypothesize that 1) TMS will have focal effects detected from surface electrodes underlying the stimulation site as well as network-level engagement detected at remote sites, 2) Repetitive TMS will induce frequency-specific effects that differ between 0.5 and 10 Hz stimulation protocols, and 3) the magnitude of repetitive TMS-evoked iEEG responses across electrodes will relate to the strength of rs-fcMRI between the stimulation and recording sites. By investigating the electrophysiological responses of TMS with high spatiotemporal precision in humans, this study will provide new mechanistic insights into the effects of TMS on target engagement and relate these findings to imaging methods already in widespread use. Moreover, the TMS will be applied in a clinically meaningful way by targeting the left dorsolateral prefrontal cortex in a protocol used to treat depression. Generating results for these aims will be key to advancing our understanding of how TMS engages brain networks, which can be leveraged to rationally develop personalized, imaging-guided therapeutic TMS for depression and other disorders.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Participant will receive active and sham stimulation at varying points during the study.
Primary Purpose: Basic Science
Official Title: Investigating the Effects of Transcranial Magnetic Stimulation With Intracranial EEG in Humans
Actual Study Start Date : October 8, 2018
Estimated Primary Completion Date : October 2025
Estimated Study Completion Date : October 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TMS in patients with intracranial electrodes
We will administer transcranial magnetic stimulation to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
Device: Transcranial magnetic stimulation
TMS is applied to the brain.




Primary Outcome Measures :
  1. Change in brain activity assessed with intracranial EEG [ Time Frame: Activity changes within seconds of the stimulation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible subjects will include neurosurgery patients (age 18 - 75) who have implantation of intracranial electrodes and undergo long term (about 2 weeks) EEG monitoring in order to decide candidacy for surgical resection of seizure foci. They must have the cognitive capacity to understand the risks and benefits fo the study and provide consent.

Exclusion Criteria:

Those who are known to have neurological or psychiatric disorder other than primary disease for which patients have surgery will be excluded.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03702127


Locations
Layout table for location information
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Investigators
Layout table for investigator information
Principal Investigator: Aaron Boes, MD, PhD University of Iowa

Layout table for additonal information
Responsible Party: Aaron Boes, Assistant Professor, University of Iowa
ClinicalTrials.gov Identifier: NCT03702127     History of Changes
Other Study ID Numbers: 201707763
First Posted: October 10, 2018    Key Record Dates
Last Update Posted: October 10, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Drug Resistant Epilepsy
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases